Evidence map›Paper›PMID 32363120›Full record

ArticleOncoimmunology2020

Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy.

Cyrill A Rentsch, Piet Bosshard, Grégoire Mayor, Malte Rieken, Heike Püschel, Grégory Wirth, Richard Cathomas, Gerald P Parzmair, Leander Grode, Bernd Eisele and 11 more

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Emerging molecular therapies in the treatment of bladder cancer.Exploration of targeted anti-tumor therapy · 2024
    Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 5 countries.

Cyrill A RentschDepartment of Urology, University Hospital Basel, University of Basel, Basel, Switzerland.
Piet BosshardDepartment of Urology, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0001-8203-4463
Grégoire MayorDepartment of Urology, University Hospital Geneva, University of Geneva, Geneva, Switzerland.
Malte RiekenDepartment of Urology, University Hospital Basel, University of Basel, Basel, Switzerland.
Heike PüschelDepartment of Urology, University Hospital Basel, University of Basel, Basel, Switzerland.
Grégory WirthDepartment of Urology, University Hospital Geneva, University of Geneva, Geneva, Switzerland.
Richard CathomasDepartment of Oncology, Cantonal Hospital Chur, Chur, Switzerland.
Gerald P ParzmairVakzine Projekt Management GmbH, Hannover, Germany.
Leander GrodeVakzine Projekt Management GmbH, Hannover, Germany.
Bernd EiseleVakzine Projekt Management GmbH, Hannover, Germany.
Hitt SharmaSerum Institute of India Pvt. Ltd., Pune, India.
Manish GuptaSerum Institute of India Pvt. Ltd., Pune, India.
Sunil GairolaSerum Institute of India Pvt. Ltd., Pune, India.ORCID 0000-0003-4093-9736
Umesh ShaligramSerum Institute of India Pvt. Ltd., Pune, India.
Daniel GoldenbergerDepartment of Clinical Bacteriology & Mycology, University Hospital Basel, University of Basel, Basel, Switzerland.
François SpertiniDivision of Immunology and Allergy, Lausanne University Hospital, Lausanne, Switzerland.
Régine AudranDivision of Immunology and Allergy, Lausanne University Hospital, Lausanne, Switzerland.ORCID 0000-0002-5071-8403
Milica EnoiuSAKK Coordinating Center, Bern, Switzerland.
Simona BerardiSAKK Coordinating Center, Bern, Switzerland.
Stefanie HayozSAKK Coordinating Center, Bern, Switzerland.ORCID 0000-0002-2265-6559
Andreas WickiDepartment of Oncology, University Hospital Basel, University of Basel, Switzerland.
University of Basel · CHSerum Institute of India (India) · INRazi Hospital · IRThe Coordinating Center · USUniversity of Geneva · CHUniversity of Lausanne · CHHospital Base · CLUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BCG VaccineMycobacterium bovisUrinary Bladder NeoplasmsAdministration, IntravesicalAgedAged, 80 and overHumansMaleBCG VaccineBCG-failureclinical trialGMO (genetically modified organism)listeriolysinNMIBC (Non-muscle-invasive bladder cancer)

Identifiers

PMID32363120
PMCPMC7185202
OpenAlexW3020037686

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.